[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Diarrhea pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 145 pages | ID: D980E4DCA510EN
VPAResearch

US$ 1,599.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
2020 Diarrhea PIPELINE HIGHLIGHTS
Diarrhea is one of the widely researched conditions during 2020 with 29 companies actively focusing on realizing pipeline’s potential. Development of Diarrhea medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Diarrhea market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Diarrhea.

Good progress is anticipated during 2020 and 2021 with Diarrhea pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Diarrhea pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Diarrhea DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Diarrhea pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Diarrhea pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Diarrhea presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Diarrhea pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Diarrhea DRUG PROFILES
Diarrhea development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-
  • Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
  • Phase of development
  • Mechanism of Action
  • Route of Administration
  • Companies involved including originator, licensing companies, developer, investors, and others
  • New molecular entity details
  • Orphan drug designation and other special status provided by regulators
Diarrhea COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Diarrhea drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Diarrhea. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 29 Diarrhea companies including company overview, key snapshot, contact information, and their strategies on accelerating Diarrhea pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Akthelia Pharmaceuticals, Albireo Pharma Inc, Allergan Plc, AzurRx BioPharma Inc, Boston Pharmaceuticals Inc, Chongqing Zhifei Biological Products Co Ltd, Codagenix Inc, Cosmo Pharmaceuticals NV, DiscoveryBiomed Inc, Glycosyn LLC , Immuron Ltd, Kaleido Biosciences Inc, Kuhnil Pharmaceutical Co Ltd, Miyarisan Pharmaceutical Company Ltd, Napo Pharmaceuticals In, Nippon Shinyaku Co Ltd , Novartis AG , OnQuality Pharmaceuticals (USA) LLC, Orphomed Inc, Prokarium Ltd , Protagonist Therapeutics Inc, RaQualia Pharma Inc , Rebiotix Inc, RedHill Biopharma Ltd, RxBio Inc , Scandinavian Biopharma Holding AB, Synthetic Biologics Inc , Syntiron LLC, VenatoRx Pharmaceuticals Inc

REASONS TO BUY
  • The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
  • This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
  • Buyers can identify most promising drug candidates for treatment of Diarrhea
  • It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
  • Users can estimate possible delays in the delivery of pipeline or launch of new products
  • Stay ahead of competition through understanding their pipeline progression, strategies and outlook
  • The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
  • Optimize your licensing and technology transfer strategies through identification of prospect partners
1. INTRODUCTION TO DIARRHEA

1.1 Diarrhea- Disease overview
1.2 Diarrhea- Market Size
1.3 Diarrhea- Companies Involved

2. DIARRHEA PIPELINE SNAPSHOT- 2020

2.1 Diarrhea Pipeline by Phase
2.2 Diarrhea Pipeline by Mechanism of Action
2.3 Diarrhea Pipeline by Route of Administration
2.4 Diarrhea Pipeline- New Molecular Entities
2.5 Diarrhea Pipeline- Orphan Drug Designation/ Special Designation

3. DIARRHEA DRUG PROFILES

3.1 Current Status
3.2 Diarrhea Drug Snapshot
3.3 Diarrhea Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Akthelia Pharmaceuticals Diarrhea Pipeline Insights and Clinical Trials
4.2 Albireo Pharma Inc Diarrhea Pipeline Insights and Clinical Trials
4.3 Allergan Plc Diarrhea Pipeline Insights and Clinical Trials
4.4 AzurRx BioPharma Inc Diarrhea Pipeline Insights and Clinical Trials
4.5 Boston Pharmaceuticals Inc Diarrhea Pipeline Insights and Clinical Trials
4.6 Chongqing Zhifei Biological Products Co Ltd Diarrhea Pipeline Insights and Clinical Trials
4.7 Codagenix Inc Diarrhea Pipeline Insights and Clinical Trials
4.8 Cosmo Pharmaceuticals NV Diarrhea Pipeline Insights and Clinical Trials
4.9 DiscoveryBiomed Inc Diarrhea Pipeline Insights and Clinical Trials
4.10 Glycosyn LLC Diarrhea Pipeline Insights and Clinical Trials
4.11 Immuron Ltd Diarrhea Pipeline Insights and Clinical Trials
4.12 Kaleido Biosciences Inc Diarrhea Pipeline Insights and Clinical Trials
4.13 Kuhnil Pharmaceutical Co Ltd Diarrhea Pipeline Insights and Clinical Trials
4.14 Miyarisan Pharmaceutical Company Ltd Diarrhea Pipeline Insights and Clinical Trials
4.15 Napo Pharmaceuticals In Diarrhea Pipeline Insights and Clinical Trials
4.16 Nippon Shinyaku Co Ltd Diarrhea Pipeline Insights and Clinical Trials
4.17 Novartis AG Diarrhea Pipeline Insights and Clinical Trials
4.18 OnQuality Pharmaceuticals (USA) LLC Diarrhea Pipeline Insights and Clinical Trials
4.19 Orphomed Inc Diarrhea Pipeline Insights and Clinical Trials
4.20 Prokarium Ltd Diarrhea Pipeline Insights and Clinical Trials
4.21 Protagonist Therapeutics Inc Diarrhea Pipeline Insights and Clinical Trials
4.22 RaQualia Pharma Inc Diarrhea Pipeline Insights and Clinical Trials
4.23 Rebiotix Inc Diarrhea Pipeline Insights and Clinical Trials
4.24 RedHill Biopharma Ltd Diarrhea Pipeline Insights and Clinical Trials
4.25 RxBio Inc Diarrhea Pipeline Insights and Clinical Trials
4.26 Scandinavian Biopharma Holding AB Diarrhea Pipeline Insights and Clinical Trials
4.27 Synthetic Biologics Inc Diarrhea Pipeline Insights and Clinical Trials
4.28 Syntiron LLC Diarrhea Pipeline Insights and Clinical Trials
4.29 VenatoRx Pharmaceuticals Inc Diarrhea Pipeline Insights and Clinical Trials

5. DIARRHEA MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information


More Publications